Stock Events

Axonics 

$70.29
13
+$0.01+0.01% Today

Statistics

Day High
70.31
Day Low
70.2
52W High
70.53
52W Low
48.3
Volume
167,439
Avg. Volume
384,423
Mkt Cap
3.54B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.38
-0.21
-0.04
0.13
Expected EPS
0.112267
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AXNX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap113.61B
Medtronic is a major competitor in the neuromodulation market, offering products that directly compete with Axonics' sacral neuromodulation devices for bladder and bowel control.
Boston Scientific
BSX
Mkt Cap120.45B
Boston Scientific competes in the neuromodulation space, particularly in pelvic health solutions, which overlaps with Axonics' product offerings.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie, through its acquisition of Allergan, owns Latisse, which competes in the broader neuromodulation and urology markets relevant to Axonics' interests.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk competes indirectly through their treatments for conditions like diabetes, which can have urological complications that products from Axonics aim to address.
Pfizer
PFE
Mkt Cap164.39B
Pfizer offers products in the urology segment, including treatments for overactive bladder, which is a condition Axonics' devices aim to treat.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its medical devices division, offers products that can be used in surgical procedures related to urology and pelvic health, competing with Axonics.
Smith & Nephew
SNN
Mkt Cap13.45B
Smith & Nephew, while primarily focused on orthopedics, has products in the wound care space that could indirectly compete with Axonics in post-operative care for pelvic health procedures.
Stryker
SYK
Mkt Cap137.35B
Stryker operates in the medical technology field with a broad portfolio that could compete with Axonics in surgical equipment and devices for urology and neuromodulation procedures.
Zimmer Biomet
ZBH
Mkt Cap23.51B
Zimmer Biomet, mainly focused on orthopedics, has been expanding into new areas, including minimally invasive therapies that could compete with Axonics' neuromodulation devices.
Edwards Lifesciences
EW
Mkt Cap42.14B
Edwards Lifesciences, known for heart valves, also explores areas in medical technologies that could intersect with Axonics' focus on neuromodulation and pelvic health.

Analyst Ratings

0$Average Price Target
The highest estimate is $0.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Show more...
CEO
Raymond Cohen
Employees
797
Country
US
ISIN
US05465P1012

Listings